乙型病毒性肝炎合并2型糖尿病临床分析

Analysis of treatment of Hepatitis B patients with type 2 diabetes

目的探讨乙型病毒性肝炎合并2型糖尿病患者使用干扰素抗病毒治疗的有效性与安全性。方法随机选取2013年2月—2015年2月荥阳市人民医院收治的乙型病毒性肝炎合并2型糖尿病患者50例,将其设为研究组,同期收治的乙型病毒性肝炎未合并2型糖尿病患者50例,设为对照组。研究组患者在抗病毒治疗前停用口服降糖药,统一改用注射胰岛素控制血糖,待用药1周血糖控制在正常范围后开始予以抗病毒治疗。治疗开始后的第1、12、24、36、48周检测HBV-DNA指标,并于满疗程治疗结束后,测定两组患者的空腹血糖、餐后2h血糖、糖化血红蛋白及肝功能,比较两组患者的抗病毒应答及血糖变化情况。结果治疗后研究组与对照组的ALT水平、空腹血糖、餐后2h血糖、糖化血红蛋白及HBV-DNA阴转率差异均无统计学意义(P>0.05)。结论密切监测下应用干扰素治疗乙型病毒性肝炎合并2型糖尿病是安全、有效的。

Objective To discuss the efficacy and safety if hepatitis B patients with type 2 diabetes treated with interfer- on antiviral. Methods Randomly selected in February 2013） February 2015 50 cases of hepatitis B patients with type 2 diabetes in our hospital, set research group, over the same period of hepatitis B treated type 2 diabetes patients were on- ly 50 cases, to the control group. Study group patients before antiviral therapy out of oral hypoglycemic agents, insulin injections to control blood sugar unified switch, wait a week medication blood glucose control in the normal range after starting to be anti -viral therapy. 1,12,24,36,48 weeks of treatment to detect HBV - DNA index after the start and af- ter the end of the full course of treatment, the two groups were measured fasting blood glucose, postprandial 2h blood glucose,HbAlc and liver function, two groups were compared and antiviral response changes in blood sugar. Results ALT levels after treatment group and the control group, fasting blood glucose, postprandial 2h blood glucose, HbAlc and HBV - DNA negative conversion rate was no significant difference （P 〉 O. 05）. Conclusion Closely monitored in- terferon treatment of hepatitis B patients with type 2 diabetes are safe and effective.